Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Apr 2017
Review Meta AnalysisSystematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Biosimilars of anti-tumour necrosis factor (TNF)-α agents have now become clinically available for the treatment of inflammatory bowel diseases (IBD). ⋯ CT-P13 was associated with excellent clinical efficacy and safety profile, supporting its use in the treatment of IBD.